---
title: "Illumina Inc. Stock Underperforms Thursday When Compared To Competitors"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286471117.md"
description: "Illumina Inc. (ILMN) shares fell 1.21% to $143.24 on Thursday, marking the second consecutive day of losses, despite a positive trading session for the overall market. The stock is currently 7.90% below its 52-week high of $155.53. In comparison, competitors Labcorp Holdings Inc. (LH), Charles River Laboratories (CRL), and Quest Diagnostics (DGX) also experienced declines. Trading volume for Illumina was 2.0 million, surpassing its 50-day average of 1.5 million."
datetime: "2026-05-14T21:23:43.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286471117.md)
  - [en](https://longbridge.com/en/news/286471117.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286471117.md)
---

# Illumina Inc. Stock Underperforms Thursday When Compared To Competitors

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Illumina Inc. (ILMN) slid 1.21% to $143.24 Thursday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index rising 0.77% to 7,501.24 and the Dow Jones Industrial Average rising 0.75% to 50,063.46.

This was the stock's second consecutive day of losses.

Illumina Inc. closed 7.90% short of its 52-week high of $155.53, which the company achieved on January 22nd.

The stock demonstrated a mixed performance when compared to some of its competitors Thursday, as Labcorp Holdings Inc. (LH) fell 0.16% to $254.02, Charles River Laboratories International Inc. (CRL) fell 2.29% to $159.12, and Quest Diagnostics Inc. (DGX) fell 1.52% to $187.94.

Trading volume (2.0 M) eclipsed its 50-day average volume of 1.5 M.

Data source: Dow Jones Market Data, FactSet. Data compiled May 14, 2026.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

05-14-26 1723ET

### Related Stocks

- [ILMN.US](https://longbridge.com/en/quote/ILMN.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [LH.US](https://longbridge.com/en/quote/LH.US.md)
- [CRL.US](https://longbridge.com/en/quote/CRL.US.md)
- [DGX.US](https://longbridge.com/en/quote/DGX.US.md)
- [.SPX.US](https://longbridge.com/en/quote/.SPX.US.md)
- [.DJI.US](https://longbridge.com/en/quote/.DJI.US.md)
- [FDS.US](https://longbridge.com/en/quote/FDS.US.md)

## Related News & Research

- [BUZZ-Illumina up after CEO to join Trump's China trip](https://longbridge.com/en/news/286125552.md)
- [Co-Diagnostics Advances Ebola Preparedness With New Bundibugyo Virus Assay Strategy; Stock Up](https://longbridge.com/en/news/286956797.md)
- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)
- [Genprex data shows gene therapy reverses hyperglycemia in T2D mice at ASGCT](https://longbridge.com/en/news/286414681.md)
- [Regenxbio's muscle disorder therapy meets main goal in late-stage study](https://longbridge.com/en/news/286406339.md)